Dr. Fred Beasley provides an overview of study design, criteria for defining your study aim and expert advice for selecting the ideal rodent model for your preclinical obesity research.

During this presentation, Dr. Fred Beasley will give a broad-level overview of the factors to consider when deciding on an appropriate preclinical rodent model for studying obesity and its treatments. It will feature an overview of trends in obesity and associated illnesses, and the role of pharmacological intervention. Dr. Beasley will discuss criteria for establishing a study’s aims and review commonly used rodent models obesity, addressing both genetically inherited and diet-induced animal models. The webinar will conclude with additional considerations for improving your study design.

Key Topics Include:

  • An introduction to the role of pharmacological intervention in treating obesity
  • A guide to establishing study aims for obesity research
  • An overview of commonly used rodent obesity models (diet and genetic)
  • Additional considerations for obesity research study design

Key methods reviewed will include…

Pharmacotherapy, diet induced obesity, Western-style diet, monogenic obese rodents, polygenic obese rodents, NAFLD activity score

Presenters

Director of Scientific Engagement, Cardiovascular and Metabolic Disease
CrownBio

Production Partner

CrownBio

CrownBio is a Cutting Edge Translational Technology Company Making Precision Medicine a Reality.

Additional Content From CrownBio

ADA 2020 CrownBio Virtual Event

ADA 2020 CrownBio Virtual Event

Explore CrownBio’s virtual American Diabetes Association 2020 event to catch up with the latest preclinical research on diabetes, NAFLD/NASH, obesity, cardiovascular and renal diseases.

Additional Content From American Physiological Society

Targeting Biological Aging: A New Paradigm for 21st Century Medicine

Targeting Biological Aging: A New Paradigm for 21st Century Medicine

During this webinar, Dr. Matt Kaeberlein will provide an overview of translational geroscience, which he believes will become the paradigm for the practice of medicine in the 21st century. He will also discuss recent work with one such intervention, the drug rapamycin, and its potential to enhance healthspan in companion dogs and people.

Related Content